The European Commission has approved Kimberly-Clark’s proposed $40 billion acquisition of Kenvue, the consumer health company behind brands such as Tylenol, on October 13, 2026.
However, the EU approval for Kimberly-Clark Kenvue acquisition comes with conditions designed to protect competition in feminine hygiene markets. Kimberly-Clark must sell its tampon and other feminine hygiene brands in the European Economic Area (EEA) to address concerns about reduced competition.
The Commission has also approved Turkey-based Dilek Gıda Üretim ve Pazarlama Ticaret A.Ş. as the buyer of the divested business.
How Did the EU Approval of Kenvue Acquisition Happen?
The European Commission reviewed the Kimberly-Clark Kenvue deal under the EU Merger Regulation, which allows regulators to assess major mergers and acquisitions for their potential impact on competition.
Kimberly-Clark, a US-based consumer products company, is known for brands such as Huggies and Kleenex. Kenvue manufactures consumer health and personal care products, including Tylenol, Listerine, Nicorette, and Neutrogena.
The proposed Kenvue acquisition would bring the companies’ product portfolios under common ownership, expanding Kimberly-Clark’s presence across personal care and consumer health categories. However, the EU approval for Kimberly-Clark Kenvue acquisition depends on Kimberly-Clark fully meeting the agreed conditions.
Why the EU Raised Competition Concerns in the Supplier Market?
The Commission’s investigation identified potential competition problems in the tampon markets of Czechia, Estonia, and Slovakia. Regulators were concerned that the Kimberly-Clark Kenvue deal could remove an important supplier in markets where relatively few other suppliers operate.
This could weaken competition in those specific markets. The Commission therefore required changes to the transaction before granting EU approval for Kimberly-Clark Kenvue acquisition.
The concerns were focused on overlapping feminine hygiene businesses rather than the companies’ entire product portfolios. The regulator assessed whether the proposed remedies would allow the acquisition to proceed without significantly reducing competition.
Which Brands Will Be Sold Under Kenvue Acquisition?
To address the regulator’s concerns, Kimberly-Clark committed to divesting its tampon and other feminine hygiene brands across the EEA.
The feminine hygiene brand divestment includes:
- Kotex, including the Lidie sub-brand
- Camelia
- Record
The Kenvue acquisition conditions and commitment cover more than the brand names. It also includes associated intellectual property rights, technical know-how, key employees, and business relationships needed to operate the business.
The conditions apply to the relevant regional business and assets. They should not be interpreted as a requirement to sell these brands worldwide.
This EU approval for Kimberly-Clark Kenvue acquisition is intended to remove the overlap between the companies’ feminine hygiene activities in the EEA that raised competition concerns.
What Happens To the Divested Business Dilek Gıda Acquisition?
The European Commission has approved Dilek Gıda Üretim ve Pazarlama Ticaret A.Ş., a Turkey-based distributor of consumer goods, as the purchaser of the business Kimberly-Clark must sell.
The Commission reviewed Dilek’s business plan with support from an independent adviser. It concluded that the buyer had the financial resources and operational expertise to maintain and develop the business as a viable competitor.
The Commission also amended the proposed commitments after receiving feedback through a market test, a process regulators use to assess whether proposed remedies adequately address competition concerns.
The Dilek Gıda acquisition is therefore a central part of the regulatory solution, helping preserve a competitive supplier in the affected markets.
What Happens After the EU Approval for Kimberly-Clark Kenvue Acquisition?
The EU approval for Kimberly-Clark Kenvue acquisition remains conditional on full compliance with the commitments.
An independent trustee will monitor implementation under the European Commission’s supervision. This oversight is intended to ensure that Kimberly-Clark fulfils its obligations and that the divested business can continue operating as a competitive force.
Regulatory clearance does not, by itself, confirm that the overall Kimberly-Clark Kenvue deal has closed. Its completion should be distinguished from the European Commission’s approval decision.
